Asset Details
Do you wish to reserve the book?
Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis
Do you wish to request the book?
Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Relationship between BMI and chemotherapy-induced peripheral neuropathy in cancer patients: a dose-response meta-analysis
2025
Overview
Objective
This meta-analysis aimed to evaluate the dose-response relationship between body mass index (BMI) and the risk of chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients.
Methods
We conducted a dose-response meta-analysis of 10 studies involving 6,841 cancer patients. Studies reporting BMI and CIPN outcomes were selected. The relationship between BMI and CIPN was assessed using random-effects models and restricted cubic splines to model the dose-response association.
Results
Pooled analysis revealed a significant association between higher BMI and increased risk of CIPN, with an odds ratio (OR) of 1.55 (95% CI, 1.20–1.99). A dose-response analysis demonstrated a clear linear relationship between BMI and the risk of CIPN. For every 5 kg/m
2
increase in BMI, the relative risk of CIPN increased by approximately 15%. Subgroup analyses showed stronger associations in breast cancer patients and those treated with taxane or platinum-based regimens. Sensitivity analyses confirmed the robustness of the results, and mild publication bias was observed.
Conclusions
Higher BMI is significantly associated with an increased risk of CIPN, with a dose-dependent effect. Weight management interventions, such as dietary modifications and physical activity, may reduce CIPN risk, particularly in patients with elevated BMI undergoing chemotherapy with neurotoxic regimens.
Publisher
BioMed Central,BioMed Central Ltd,BMC
Subject
/ Antineoplastic Agents - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ BMI
/ Cancer
/ Chemotherapy-Induced Peripheral Neuropathy
/ Diabetes
/ Dose-Response Relationship, Drug
/ Exercise
/ Humans
/ Medicine
/ Methods
/ Obesity
/ Peripheral Nervous System Diseases - chemically induced
/ Peripheral Nervous System Diseases - epidemiology
/ Risk
